Skip to content

OCS Liver Perfusion (OLP) Post-Approval Registry

OCS Liver Perfusion (OLP) Post-Approval Registry

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05074160
Enrollment
166
Registered
2021-10-12
Start date
2021-10-14
Completion date
2026-06-30
Last updated
2025-04-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Transplant

Brief summary

The objective of the OLP Registry is to collect more data on the post-transplant clinical outcomes of DBD and DCD donor livers preserved and assessed on OCS Liver System according to the approved indication and the OCS device performance in the real-world setting.

Detailed description

OLP Registry is a multi-center, observational post-approval registry of adult primary liver transplant recipients who are transplanted with an OCS Liver-perfused DBD or DCD donor liver according to the approved indication and that match the eligibility criteria below.

Interventions

DEVICEOCS Liver

Multi-center, observational post-approval registry of adult primary liver transplant recipients who are transplanted with an OCS Liver-perfused DBD or DCD donor liver according to the approved indication and that match the eligibility criteria below.

Sponsors

TransMedics
Lead SponsorINDUSTRY

Study design

Observational model
OTHER
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult primary liver transplant recipients of DBD or DCD donor Livers perfused on OCS Liver System Donor

Exclusion criteria

* Donor livers with accessory arterial blood supply requiring back table anastomosis, major traumatic injury, or hematoma; or * Split donor liver; or * DCD donor liver with \>30 minutes of warm ischemic time (defined as from withdrawal of life support until donor liver cold flush); or * DCD donors age \>55 years; or * DCD donor liver with macrosteatosis of \>15% * Living donors * Donors with positive serology for HIV, Hep B and C * Donors with macrosteatosis of ≥40% Recipient

Design outcomes

Primary

MeasureTime frameDescription
Patient Survival1 year post-Liver transplant1-year patient survival with the originally transplanted liver (patient and graft survival) post-Liver transplant.

Other

MeasureTime frameDescription
Safety Endpoint6 months post-Liver transplant6-months liver graft survival post-Liver transplant
Long Term Patient Survival2 years post-transplantK-M Patient survival at 1- and 2-years post-transplant
Long Term Graft Survival2 years post-transplantK-M Graft survival at 6 months, 1- and 2-years post-transplant

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026